Brown Brothers Harriman & Co. Buys 31 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Brown Brothers Harriman & Co. increased its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4.4% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 743 shares of the company’s stock after acquiring an additional 31 shares during the quarter. Brown Brothers Harriman & Co.’s holdings in IDEXX Laboratories were worth $375,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of IDXX. B. Riley Wealth Advisors Inc. grew its holdings in IDEXX Laboratories by 35.8% during the first quarter. B. Riley Wealth Advisors Inc. now owns 1,879 shares of the company’s stock worth $1,015,000 after buying an additional 495 shares in the last quarter. Tidal Investments LLC grew its holdings in IDEXX Laboratories by 71.4% during the first quarter. Tidal Investments LLC now owns 4,373 shares of the company’s stock worth $2,361,000 after buying an additional 1,821 shares in the last quarter. Comerica Bank grew its holdings in IDEXX Laboratories by 2.0% during the first quarter. Comerica Bank now owns 29,041 shares of the company’s stock worth $15,681,000 after buying an additional 577 shares in the last quarter. Hancock Whitney Corp bought a new stake in IDEXX Laboratories during the first quarter worth $220,000. Finally, Plato Investment Management Ltd grew its holdings in IDEXX Laboratories by 1,675.3% during the first quarter. Plato Investment Management Ltd now owns 1,509 shares of the company’s stock worth $815,000 after buying an additional 1,424 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on IDXX. Piper Sandler restated a “neutral” rating and issued a $435.00 price objective (down previously from $520.00) on shares of IDEXX Laboratories in a research note on Monday, November 4th. JPMorgan Chase & Co. reduced their price objective on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating for the company in a research note on Friday, October 11th. Stifel Nicolaus reduced their price objective on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a research note on Thursday, October 10th. Finally, Barclays reduced their price objective on IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating for the company in a research note on Monday, November 4th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and an average price target of $552.38.

IDEXX Laboratories Stock Up 1.1 %

Shares of NASDAQ IDXX opened at $421.76 on Thursday. IDEXX Laboratories, Inc. has a one year low of $398.50 and a one year high of $583.39. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.42 and a quick ratio of 1.03. The business’s fifty day moving average price is $455.52 and its 200-day moving average price is $479.07. The stock has a market capitalization of $34.54 billion, a PE ratio of 40.67, a P/E/G ratio of 3.74 and a beta of 1.36.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Thursday, October 31st. The company reported $2.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.69 by $0.11. The business had revenue of $975.50 million for the quarter, compared to analysts’ expectations of $980.32 million. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The firm’s quarterly revenue was up 6.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.53 EPS. On average, equities research analysts anticipate that IDEXX Laboratories, Inc. will post 10.43 EPS for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.